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Abstract 
Sulfated polysaccharides constitute a large and complex group of macromolecules which 
possess a wide range of important biological properties. Many of them hold promise as new 
therapeutics, but determination of their blood levels during pharmacokinetic studies can be 
challenging. Heparin Red, a commercial mix-and-read fluorescence assay, has recently 
emerged as a tool in clinical drug development and pharmacokinetic analysis for the 
quantification of sulfated polysaccharides in human plasma. The present study describes the 
application of Heparin Red to the detection of heparin, a highly sulfated polysaccharide, and 
fucoidan, a less sulfated polysaccharide, in spiked mouse and rat plasmas. While the 
standard assay protocol for human plasma matrix gave less satisfactory results, a modified 
protocol was developed that provides within a detection range 0-10 µg per mL better limits of 
quantification, 1.1 – 2.3 µg per mL for heparin, and 1.7 – 3.4 µg per mL for fucoidan. The 
required plasma sample volume of only 20 µL is advantegous in particular when blood 
samples need to be collected from mice. Our results suggest that Heparin Red is a promising 
tool for the preclinical evaluation of sulfated polysaccharides with varying sulfation degrees in 
mouse and rat models.   
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Introduction 
Sulfated polysaccharides constitute a large and complex group of macromolecules known to 
possess a wide range of important biological properties. Heparin (scheme 3, left), a naturally 
occuring, polydisperse polysaccharide belonging to the glycosaminoglycan family, is of 
tremendous clinical importance as an anticoagulant drug. It has long been known to have 
biological effects that are unrelated to its anticoagulant activity, and there has been a recent 
burgeoning of interest in therapeutic applications of heparins and related sulfated 
polysaccharides beyond anticoagulant activity.[1,2]  
 
Examples of “non-anticoagulant” sulfated polysaccharides in advanced clinical trials include 
tafoxiparin [3] (a chemically modified heparin, used for the treatment of prolonged labour), 
sevuparin [4] (a chemically modified heparin, treatment for sickle cell disease), muparfostat 
[5] (synthetic sulfated pentasaccharide, liver cancer), pixatimod [6] (highly sulfated synthetic 
tetrasaccharide, solid tumors), roneparstat [7] (chemically modified heparin, advanced 
multiple myeloma) and ibsolvmir [8] (dextran sulfate, preventing rejection of transplanted 
pancreatic  islet cells in diabetes patients). Many more sulfated polysaccharides that hold 
promise as new therapeutics are in earlier or later stages of pre-clinical development, as 
highlighted by recent reviews.[9-12] For example, algae-derived polysaccharides such as 
fucoidans (scheme 3, right) have an attractive  array of biological activities with potential 
health benefits.[13-14]  
 
For both clinical and preclinical drug development, pharmacokinetic analysis needs to be 
considered.  A fundamental requirement for understanding the pharmacokinetics of sulfated 
polysaccharides is the availability of robust analytical methods, in particular for determining 
the blood levels of the target compound. The structural complexity makes the quantification 
of sulfated polysaccharides in complex matrices such as blood plasma challenging, in 
particular if the compounds lack siginificant anticoagulant activity so that the clinically 
established, indirect heparin assays based on interaction with coagulation factors are not 
sufficiently sensitive. Methods based on isolation of the sulfated polysaccharides or – if 
available - enzyme linked immunosorbent assays involve tedious, time consuming multistep 
protocols and are not first choice for the analysis of large sample numbers in preclinical or 
clinical trials.  
  
The drawbacks of analytical methods for sulfated polysaccharides have stimulated the 
development of simple direct detection methods with cationic dyes that change absorbance 
or fluorescence upon binding of the polyanionic target. [15] Very few such dye-based assays, 
however, are commercially and widely available to a broad community of researchers and 
 
clinicians. Heparin Red is a commercial fluorescent molecular probe for the detection of 
sulfated polysaccharides in plasma with outstanding sensitivity in the low µg/mL range.[16] It 
is a polyamine functionalized, red-fluorescent perylene diimide derivative (scheme 1) that 
strongly binds  polyanionic polysaccharides so that aggregation of dye molecules results in 
contact quenching of fluorescence (scheme 2).[17, 18]  
 
                               
Scheme 1. Structure of Heparin Red.    
 
 
Scheme 2. Schematic representation of fluorescence quenching of the molecular probe Heparin Red 
in the presence of polyanionic polysaccharides.     
 
The commercial Heparin Red Kit has been applied to the sensitive quantification in human 
plasma of unfractionated and low-molecular-weight heparins [19], heparin octa- and 
decasaccharides [19], chemically modified heparins including tafoxiparin [19], heparan 
sulfate [20], algae-derived fucoidans [21], carrageenan [22] and ulvan [22], and the semi-
synthetic polysaccharides dextran sulfate [22] and sulfated hyaluronic acid [22]. Heparin Red 
is used for pharmacokinetic studies in several of the abovementioned clinical trials of sulfated 
polysaccharide drug candidates.[23] All these applications of Heparin Red have focused so 
far on the human plasma matrix. For preclinical studies, mice and rats are the most widely 
used model organisms. Human, mouse and rat plasma differ in protein composition.[24] 
Human serum albumin, the most abundant plasma protein, shares only about 70% amino 
acid sequence homology with mouse and rat albumin.[25] Consequently, binding of small 
molecules and drugs to albumin and other plasma proteins can differ significantly between 
human and animal species.[26] Another particularity is the small body size and limited blood 
 
volume of rats and especially mice. Quantitative assays for drug exposure that require large 
blood or plasma sample volumes may not comply with animal welfare guidelines.[27]  
 
The present study describes for the first time the application the Heparin Red to the detection 
of sulfated polysaccharides in mouse and rat plasma. Since response of Heparin Red 
depends on charge density (sufation degree, respectively) and the polysaccharides species 
in preclinical development cover a range of charge densities, we have selected as analytical 
targets heparin, a highly sulfated polysaccharide having an averaged charge of about -1.8 
per monosaccharide (scheme 3), and a fucoidan with -0.8 per monosaccharide, representing 
the less sulfated polysaccharides.  
 
 
                                   
Scheme 3. Left: Structure of the major repeating disaccharide unit of heparin. The averaged charge 
density per monosaccharide is typically -1.8.[28, 29]  Right: Repeating sulfated fucose unit, as present 
in many fucoidans. Sulfation pattern is variable, fucose may be monosulfated, disulfated or non-
sulfated. The averaged charge density per monosaccharide of the fucoidan used in this study (from 
the brown algae species F. vesiculosus) is typically -0.8. [14, 21]  
 
 
 
Materials and Methods 
Instrumentation 
Fluorescence measurements 
Fluorescence (Heparin Red® assay) was measured with a microplate reader Biotek Synergy 
Mx (Biotek  Instruments, Winooski, VT, USA), excitation at 570 nm, emission recorded at 605 
nm,  spectral band width 13.5 nm, read height of 8 mm. Sensitivity of the instrument was 
adjusted by setting the gain 100 for heparin detection (figure 1-4) and 120 for fucoidan 
detection (figure 5-8). 
 
Microplates 
For fluorescence measurements (Heparin Red® assay) 96 well microplates, polystyrene,  
Item No 655076, were purchased from Greiner Bio-One GmbH, Frickenhausen.  
 
Pipettes  
Transferpette® 0,5-10µl, Transferpette®-8 20-200µl and Transferpette®-12 20-200µl, 
purchased from Brand GmbH, Wertheim. Rainin Pipettes 100-1000µl, 20-200µl, and 2-20µl 
purchased from Mettler Toledo, OH, USA. 
 
Reagents 
 
Heparin Red Kit 
The Heparin Red® Kit  was a gift from Redprobes UG, Münster, Germany [30]. Kit 
components: Heparin Red solution, Product No HR001, Lot 01-003, and Enhancer Solution.  
 
Sulfated polysaccharides 
Unfractionated heparin sodium salt from porcine intestine mucosa (“heparin”), was sourced 
as a solid from Sigma-Aldrich GmbH, Steinheim (product number H5515, Lot SLBK0235V, 
indicated potency 210 IU/mg). Fucoidan from from Fucus vesiculosus, purity >95%, product 
number F8190, Lot SLBN8754V, was purchased from Sigma-Aldrich GmbH, Steinheim.  
 
Plasma 
Pooled human plasma was prepared by mixing equal volumes of ten single-donor citrated 
plasmas of healthy individuals, provided by the Blood Bank of the Institute for Clinical 
Transfusion Medicine and Cell Therapy Heidelberg (IKTZ). Citrated mouse plasma, product 
number IGMS-N-N02-50, Lot Nr. 22430 (Innovative Grade, US origin)  was obtained from 
Dunn Labortechnik GmbH, Asbach. This plasma was recovered from whole blood donations 
from normal healthy CD-1 mice.  Citrated rat plasma “rat 1”, product number RTPC07, Lot 
Nr. 171023-0207 was obtained from Gentaur Molecular Products, Kampenhout, Belgium. 
This plasma was processed from the blood of healthy Sprague Dawley rats according to the 
certificate of the producer Equitech-Bio Inc.  Citrated rat plasma “rat 2”, prepared from pooled 
rat (mixture of strains) blood, lyophilized, product number P2516, Lot Nr. SLBN0606V,  was 
obtained from Sigma-Aldrich GmbH, Steinheim. This plasma was reconstituted with 1 mL 
water as recommended by the provider. Plasma as well as spiked plasma samples were 
stored at -20°C. 
 
Other 
Aqueous solutions were prepared with HPLC grade water purchased from VWR, product No 
23595.328. MgCl2 product number 68475, Lot Nr. 1151053,  was obtained from Sigma-
Aldrich GmbH, Steinheim. 
 
 
Methods 
 
Heparin Red® Kit 
Heparin, standard protocol (figure 1, 2; table 1) 
For determination of heparin in plasma samples, the protocol of the provider for a 96-well 
microplate assay was followed with a minor modification: The mixture of Heparin Red 
solution and Enhancer solution was freshly prepared in 1:90 ratio (100 µL + 9 mL).  
Heparin, protocol with added MgCl2 (figure 3, 4; table 2) 
As above, but the freshly prepared reagent mixture was 8.775 mL Enhancer solution + 225 
µL aqeous MgCl2 solution + 100 µL Heparin red solution. 
Fucoidan, modifed protocol (figure 5, 6; table 3) 
For determination of fucoidan in plasma samples, the protocol was modified as follows: The  
Heparin Red - Enhancer mixture was freshly prepared in 1:360 ratio (25 µL + 9 mL).  
Fucoidan, modifed protocol with added MgCl2 (figure 7, 8; table 1) 
As above, but the freshly prepared reagent mixture was 8.775 mL Enhancer solution + 225 
µL aqeous MgCl2 solution + 25 µL Heparin Red solution. 
 
All assays were continued as recommended by the protocol of the provider: 20 µL of the 
heparin or fucoidan spiked plasma sample was pipetted into a microplate well, followed by 80 
µl of the Heparin Red – Enhancer (MgCl2) mixture. For sample numbers > 10, a 12-channel 
pipette was used for addititon of the Heparin Red – Enhancer (MgCl2) mixture. The 
microplate was introduced in the fluorescence reader and shaken for 3 minutes, using plate 
shaking function of the reader (setting “high”), followed by fluorescence measurement within 
1 minute.  
 
Preparation of spiked plasma samples 
Plasma samples containing defined concentrations of heparins were prepared as follows: 
Aqueous solutions (2 vol%) of unfractionated heparin and fucoidan, respectively, were added 
too pooled human plasma to achieve a concentration of 10 µg/mL. Concentrations required 
for the detections were adjusted by further dilution of this 10 µg/mL stock solution with the 
same plasma. The spiked plasma samples were stored at -20°C and thawed at room 
temperature before use. 
 
Data analysis 
Data were analyzed using Excel (Microsoft Office 10). Linear regression “through origin” ( 
with y-intercept set to 1) was applied to the response curves in figure 2, 4, 6 and 8.  
Coefficients of determination (r2) in table 1-4 were determined by linear regression. 
 
Results and discussion 
Quantification of unfractionated heparin in mouse, rat and human plasma 
In a first series of measurements, the Heparin Red Kit was applied to the determination of 
heparin in spiked plasma matrices (mouse, rat1, rat2 and human) by following the standard 
protocol recommended by the provider. The fluorescence response of Heparin Red is shown 
in figure 1. Obviously, the fluorescence of Heparin Red in the heparin-free rodent plasmas is 
much lower compared with human plasma. This could be related to association of Heparin 
Red with a plasma component of the rodent plasmas that is not prevalent in human plasma, 
leading to fluorescence quenching. While the response curves for mouse and rat1 plasma 
are almost overlapping, the difference between the plasmas rat1 (not lyophilized; Sprague 
Dawley rats) and rat2 (lyophilized and reconstituted; mixture of strains) is quite significant.        
 
Figure 1. Fluorescence response (605 nm emission) of Heparin Red to heparin in four different 
plasma matrices: mouse, rat1, rat2 and human, using the protocol recommended by the provider (20 
µl plasma sample is mixed with 80 µL reagent solution in a microplate well). Heparin in µg/mL refers to 
the concentration in spiked plasma samples. Manually performed microplate assays, as described in 
the “Materials and Methods” section. Averages of duplicate determinations. 
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In spite of very different fluorescence intensity of Heparin Red in the plasma matrices (figure 
1), the normalized response to heparin (figure 2) is quite similar. Actually, response in the 
rodent plasmas is even better compared with human plasma. We speculate that 
fluorescence quenching of Heparin Red in the rodent plasmas is triggered by a weak, 
reversible interaction, and the binding equilibrium is largely shifted toward the strong complex 
with heparin (compare scheme 2).  Moreover, human plasma proteins may bind heparin 
stronger [31] than rodent plasma proteins and weaken the response of Heparin Red to 
heparin in human plasma.  
 
Figure 2. Data from figure 1, displayed as normalized fluorescence response (F/F0) of Heparin Red to 
heparin in the four different plasma matrices: human, mouse, rat1 and rat2. Linear regression “through 
origin (heparin = 0 µg/mL; F/F0 = 1)” was applied to the heparin concentration range 0-6 µg/mL.  
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The detection and quantification limits for the different plasma matrices (table 1) were 
determined based on signal-to-noise [32], by relating extrapolated response (linear 
regression “through origin” for the concentration range 0-6 µg/mL) to the standard deviation 
of blank samples (σblank) without heparin. The limit of detection (LOD) was calculated as LOD 
= 3 σblank / S (S= initial slope of response curve, see figure 2) and the limit of quantification as 
LOQ = 10 σblank / S.  
Plasma Human Mouse Rat1 Rat2 
σblank (n=8) 0.014 0.117 0.112 0.096 
r2 0.98 0.99 0.97 0.99 
LOD (µg/mL)  0.33 2.71 4.06 1.95 
LOQ (µg/mL) 1.11 9.04 13.54 6.50 
 
Table 1. σblank, coefficient of determination (r2), limit of detection (LOD) and limit of quantification 
(LOQ) for heparin in four different plasma matrices, relating to the data in figure 2. σblank is the 
standard deviation of the normalized optical signal generated by the heparin-free plasma samples. r2 
is the coefficient of determination obtained from linear regression (figure 2).  LOD = 3 σblank / S (S= 
slope of response curve, see figure 2). LOQ = 10 σblank / S. 
The low fluorescence intensity of Heparin Red in the rodent plasmas (figure 1) and poor limit 
of detection and quantification due to high standard deviation of blank samples (table 1)  
prompted us to modify the standard detection protocol by varying the composition of the 
reagent solution that is mixed with the plasma sample. A significant improvement was 
achieved by the presence of 50 mM MgCl2 in the reagent solution. Fluorescence of Heparin 
Red in the rodent plasmas increases significantly and nearly approaches the intensity 
observed in human plasma (figure 3). The effect is attributed to the Mg2+ ions since 
fluorescence is not in the same way restored by 100 mM NaCl (same concentration of 
chloride ions). Possibly, the Mg2+ cations mask anionic sites of the rodent plasma component 
that interact with Heparin Red and trigger the fluorescence decrease.  
  
Figure 3. Fluorescence response (605 nm emission) of Heparin Red to heparin in four different 
plasma matrices: mouse, rat1, rat2 and human, using a modified protocol with a reagent solution 
containing 50 mM MgCl2 (20 µl plasma sample is mixed with 80 µL reagent solution in a microplate 
well). Heparin in µg/mL refers to the concentration in spiked plasma samples. Manually performed 
microplate assays, as described in the “Materials and Methods” section. Averages of duplicate 
determinations.  
 
Comparison of the normalized fluorescence response in the presence (figure 4) and absence 
(figure 2) of MgCl2 indicates that the response of Heparin Red is somewhat diminished by 
MgCl2. Divalent magnesium ions at concentrations above the physiological level were shown 
to compete with high-affinity proteins for heparin binding.[33] Similarly, high Mg2+ 
concentrations present in the assay mixture may partially mask the interaction of Heparin 
Red with heparin.  
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Figure 4. Data from figure 3, displayed as normalized fluorescence response (F/F0) of Heparin Red to 
heparin in the four different plasma matrices: human, mouse, rat1 and rat2. Linear regression “through 
origin (heparin = 0 µg/mL; F/F0 = 1)” was applied to the heparin concentration range 0-6 µg/mL.  
A major beneficial effect of the MgCl2 additive is the significant reduction of the standard 
deviation of fluorescence in the rodent plasma blank samples in the absence of heparin. 
Consequently, plasma heparin LOD and LOQ, since proportional to σblank, are very much 
improved (table 2), in spite of the diminished response.  
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Plasma Human Mouse Rat1 Rat2 
σblank (n=8) 0.013 0.021 0.009 0.014 
r2 0.999 0.99 0.98 0.97 
LOD (IU/mL)  0.63 0.68 0.34 0.43 
LOQ (IU/mL) 2.10 2.28 1.12 1.42 
 
 
Table 2. σblank, coefficient of determination (r2), limit of detection (LOD) and limit of quantification 
(LOQ) of heparin four different plasma matrices, relating to the data in figure 4 (modified protocol). 
σblank is the standard deviation of the normalized optical signal generated by the heparin-free plasma 
samples. r2 is the coefficient of determination obtained from linear regression (figure 4).  LOD = 3 σblank 
/ S (S= slope of response curve, see figure 4). LOQ = 10 σblank / S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantification of fucoidan in mouse, rat und human plasma 
Fucoidan from the brown alga Fucus vesiculosus has a lower averaged charge density per 
monosaccharide than heparin, -0.8 vs -1.8 (scheme 3). The weaker binding of Heparin Red 
to less highly charged polysaccharides leads to a diminished response relative to heparin in 
the competitive human plasma matrix.[20, 21, 34] The reduced sensitivity toward fucoidan in 
human plasma can be counteracted by a minor modification of the standard protocol, so that 
a similar concentration range as for heparin can be addressed.  This modified protocol [21] 
uses a lower Heparin Red concentration (see “Materials and Methods” for details) and has 
also been applied to fucoidan detection in the present study. Otherwise, fucoidan 
determination in the different plasma matrices was performed and evaluated as described 
above for heparin.    
 
Figure 5. Fluorescence response (605 nm emission) of Heparin Red to F. vesiculosus  fucoidan in 
four different plasma matrices: mouse, rat1, rat2 and human, using a modified protocol (see “Materials 
and Methods” for details; 20 µl plasma sample is mixed with 80 µL reagent solution in a microplate 
well). Fucoidan in µg/mL refers to the concentration in spiked plasma samples. Manually performed 
microplate assays, as described in the “Materials and Methods” section. Averages of duplicate 
determinations. Sensitivity of the microplate reader has been adjusted (gain 120).  
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Figure 6. Data from figure 5, displayed as normalized fluorescence response (F/F0) of Heparin Red to 
fucoidan in the four different plasma matrices: human, mouse, rat1 and rat2. Linear regression 
“through origin (heparin = 0 µg/mL; F/F0 = 1)” was applied to the heparin concentration range 0-6 
µg/mL.  
Plasma Human Mouse Rat1 Rat2 
σblank (n=8) 0.031 0.046 0.071 0.03 
r2 0.95 0.97 0.98 0.91 
LOD (IU/mL)  0.60 1.03 1.63 0.62 
LOQ (IU/mL) 1.97 3.45 5.42 2.06 
Table 3. σblank, coefficient of determination (r2), limit of detection (LOD) and limit of quantification 
(LOQ) for fucoidan in four different plasma matrices, relating to the data in figure 6. σblank is the 
standard deviation of the normalized optical signal generated by the heparin-free plasma samples. r2 
is the coefficient of determination obtained from linear regression (figure 6).  LOD = 3 σblank / S (S= 
slope of response curve, see figure 6). LOQ = 10 σblank / S. 
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Fluorescence response follows similar trends as for heparin: Heparin Red fluorescence is 
lower in the rodent plasmas (figure 5), but normalized response to fucoidan comparable for 
all four plasmas (figure 6).  Compared with the standard protocol for heparin (figure 2, table 
1), standard deviation of the rodent plasma blanks is significantly smaller (table 3) for this 
modified protocol using a lower Heparin Red concentration, resulting in lower LOD and LOQ. 
Addition of MgCl2 again leads to a siginificant enhancement of Heparin Red fluorescence in 
the rodent plasmas (figure 7), along with a somewhat diminished response. The beneficial 
effect of MgCl2 on σblank, LOD and LOQ (table 4 vs table 3) for fucoidan detection is present 
but less pronounced than for heparin detection (table 2 vs table 1).     
 
 
Figure 7. Fluorescence response (605 nm emission) of Heparin Red to heparin in four different 
plasma matrices: mouse, rat1, rat2 and human, using a modified protocol with a reagent solution 
containing 50 mM MgCl2 (see “Materials and Methods” for details; 20 µl plasma sample is mixed with 
80 µL reagent solution in a microplate well). Fucoidan in µg/mL refers to the concentration in spiked 
plasma samples. Manually performed microplate assays, as described in the “Materials and Methods” 
section. Averages of duplicate determinations. Sensitivity of the microplate reader has been adjusted 
(gain 120). 
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Figure 8. Data from figure 7, displayed as normalized fluorescence response (F/F0) of Heparin Red to 
fucoidan in the four different plasma matrices: human, mouse, rat1 and rat2. Linear regression 
“through origin (heparin = 0 µg/mL; F/F0 = 1)” was applied to the heparin concentration range 0-6 
µg/mL.  
Plasma Human Mouse Rat1 Rat2 
σblank (n=8) 0.015 0.037 0.023 0.015 
r2 0.99 0.92 0.92 0.97 
LOD (IU/mL)  0.55 1.01 0.58 0.51 
LOQ (IU/mL) 1.84 3.36 1.92 1.70 
Table 4. σblank, coefficient of determination (r2), limit of detection (LOD) and limit of quantification 
(LOQ) for fucoidan in four different plasma matrices, relating to the data in figure 8. σblank is the 
standard deviation of the normalized optical signal generated by the fucoidan-free plasma samples. r2 
is the coefficient of determination obtained from linear regression (figure 8).  LOD = 3 σblank / S (S= 
slope of response curve, see figure 8). LOQ = 10 σblank / S. 
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Conclusion 
This study addresses the need for simple and user-friendly analytical methods for  
quantifying the blood levels of sulfated polysaccharides in mice and rats in the context of 
preclinical drug development. The commercially available, direct fluorescence assay Heparin 
Red was applied to the quantification of heparin, a highly sulfated polysaccharide, and 
fucoidan, a less sulfated polysaccharide, in spiked mouse and rat blood plasma samples. 
Application of a standard protocol for human plasma resulted in poorer detection sensitivities 
for the rodent plasma matrices. Quantification limits (LOQs) for both target analytes could be 
improved significantly by simple modifications of the protocol, in particular by the addition of 
magnesium chloride to the assay mixture. The improved protocol provides within the 
detection range 0-10 µg/mL the LOQs 1.1 – 2.3 µg/mL for heparin, and 1.7 – 3.4 µg/mL for 
fucoidan (LOQ is defined as 10 σblank / S, σblank being standard deviation of blank and S the 
initial slope of response curve). The low plasma sample volume of only 20 µL is advantegous 
in particular when blood samples are collected from mice.  
Heparin Red is a promising tool for the preclinical evaluation of sulfated polysaccharides that 
hold promise as new therapeutics. Polysaccharides of varying sulfation degrees are 
determined at low µg/mL levels in mouse and rat plasma by a simple mix-and-read 
microplate assay.  
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